Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
9.23
+0.23 (2.56%)
At close: Oct 24, 2025, 4:00 PM EDT
9.37
+0.14 (1.52%)
After-hours: Oct 24, 2025, 7:27 PM EDT
Lexeo Therapeutics Employees
Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$1,585,722
Market Cap
498.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LXEO News
- 4 days ago - Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering - GlobeNewsWire
- 8 days ago - Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement - GlobeNewsWire
- 8 days ago - Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 17 days ago - Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback - Seeking Alpha
- 18 days ago - Lexeo Therapeutics, Inc. - Special Call - Seeking Alpha
- 18 days ago - Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewsWire